International Business Machines Corporation vs Novartis AG: Strategic Comparison

This in-depth comparison examines International Business Machines Corporation and Novartis AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching International Business Machines Corporation on its own, evaluating Novartis AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between International Business Machines Corporation and Novartis AG is widest.

On the headline numbers, International Business Machines Corporation reports annual revenue of $67.5B against $54.5B for Novartis AG, while their respective market capitalizations stand at $230.0B and $274.1B. International Business Machines Corporation is headquartered in United States and Novartis AG operates from Switzerland, and those different home markets shape how each company competes.

International Business Machines Corporation: IBM mainframes process 87% of global credit card transactions. That single statistic — quietly persistent, rarely mentioned in technology journalism — explains why IBM exists at a scale that pure cloud narratives cannot account for. The System/360, launched in 1964 as a $5 billion bet that was the most expensive privately funded project in American history at the time, created the mainframe architecture that banks, insurers, and governments have built their core systems on for 60 years. Those systems don't migrate to AWS because the migration risk is existential. The $34 billion Red Hat acquisition in 2019 — the largest software deal in history at the time — was IBM's bet that the enterprise technology market was reorganizing around hybrid cloud rather than pure public cloud migration. The thesis is that large organizations don't move everything to a single cloud provider; they operate across multiple clouds and on-premises infrastructure simultaneously, and they need middleware, management software, and security tools that work across that heterogeneous environment. Red Hat's OpenShift platform sits at the center of that architecture. IBM Research has produced 5 Nobel Prizes and 6 Turing Awards. No other corporate research organization has that record. The depth of fundamental scientific contribution is unusual for a company that analysts primarily evaluate on quarterly consulting revenue growth. The quantum computing program, the materials science work, the AI research — these represent intellectual investments with long time horizons that don't appear in GAAP income statements until commercialization. Revenue grew from $57.4 billion in 2021 to $62.8 billion in 2024. The trajectory is modest but consistent — a company that divested its managed infrastructure services business (Kyndryl) in 2021 and rebuilt its revenue base around higher-margin software and consulting.

Novartis AG: On October 4, 2023, Novartis completed the spin-off of Sandoz, its $10 billion generics division, and became a different company than it had been the day before. The spin-off eliminated an entire revenue category — high-volume, low-margin, price-competitive generics — and concentrated the remaining $54.5 billion in FY2025 net sales on patented medicines in oncology, immunology, cardiovascular disease, and neuroscience. The result is a 42.2% core operating income margin, one of the highest in the pharmaceutical industry, on a revenue base that is growing at double digits. The decision to exit generics was a rejection of diversification as a risk management strategy. Conventional pharmaceutical wisdom holds that a generics business provides revenue stability when patent cliffs erode branded drug sales. Novartis under CEO Vas Narasimhan bet the opposite: that capital concentrated in radioligand therapies, gene therapies, and targeted oncology drugs would generate better long-term returns than capital spread across a high-volume, low-differentiation generics portfolio. FY2025 results — $54.5 billion in net sales, $17.6 billion in free cash flow, and $13.97 billion in net income — suggest the bet is working. The radioligand therapy platform is Novartis's most technically distinctive asset. Pluvicto, a prostate cancer treatment that delivers targeted radiation directly to cancer cells by binding to a protein overexpressed in prostate tumors, generated $2.0 billion in FY2025 sales, a 42% increase at constant currency. The peak sales outlook exceeds $4 billion annually. The Advanced Accelerator Applications acquisition in 2018 and the Chinook Therapeutics and MorphoSys acquisitions in 2023 and 2024 respectively were the capital deployments that built and extended this platform. Entresto, the heart failure treatment explicitly named in Medicare price negotiation proceedings under the Inflation Reduction Act, represents the primary near-term revenue risk. US government negotiation of Medicare prices directly affects the drug's pricing power in Novartis's largest single market. How Novartis navigates Entresto's pricing trajectory — and whether Cosentyx, Kisqali, and Kesimpta can offset any revenue pressure — will largely determine whether the 42.2% operating margin holds through 2026.

International Business Machines Corporation and Novartis AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between International Business Machines Corporation and Novartis AG.

International Business Machines Corporation business model: The segment operates at gross margins around 80%, reflecting the economics of enterprise software licensing and subscriptions. Gross margins in consulting hover around 27-29%, lower than software but providing essential customer access and deal flow that feeds software adoption. Revenue model: IBM has been transitioning from perpetual licenses and one-time hardware sales toward recurring revenue. The shift toward subscriptions and consumption-based pricing means IBM's revenue base is becoming more predictable, though the transition temporarily pressures top-line growth as large upfront deals convert to smaller annual payments spread over contract life. The irony is, this provides extraordinary pricing power and margin but also means the platform's relevance depends entirely on IBM's ability to keep it modern and connected to hybrid cloud architectures. The thesis was that Red Hat's open-source hybrid cloud platform would become the architectural standard for enterprise cloud, generating subscription revenue that would grow faster than IBM's legacy businesses declined.

Novartis AG business model: The pricing power inherent in the innovative pharma model allows Novartis to charge premium prices in the US market, which accounts for approximately 45% of total global sales. However, this pricing power is increasingly constrained by the US Inflation Reduction Act, which allows Medicare to negotiate drug prices. The company's response has been to shift its focus toward rare diseases and oncology, therapeutic areas where patient populations are smaller, clinical outcomes are more dramatic, and pricing pressure is less severe. The US market remains the most profitable region, contributing approximately 45% of total revenue but an even higher percentage of operating profit due to the significantly higher pricing power for innovative medicines in the United States compared to Europe and Asia. Concurrently, the company is navigating intense regulatory pricing pressure in the US, the world's most profitable pharmaceutical market. Additionally, the company's deep integration with academic medical centers through its clinical trial network creates a feedback loop of real-world data that accelerates regulatory approvals and label expansions. The Chinook assets target IgA nephropathy and atypical hemolytic uremic syndrome, rare conditions where Novartis now holds the only approved or late-stage therapies, granting it temporary monopolies with exceptional pricing power. The company's extensive experience in navigating the complex regulatory landscape for radiopharmaceuticals, which involves coordination between multiple government agencies including the FDA, the Nuclear Regulatory Commission (NRC), and the Department of Transportation (DOT), provides it with a deep institutional knowledge base that accelerates the development and commercialization of new radioligand assets. The company must also navigate the complex and evolving pricing and reimbursement landscape, particularly in the US where the implementation of the Inflation Reduction Act is expected to put significant downward pressure on drug prices.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of International Business Machines Corporation stack up against those of Novartis AG.

International Business Machines Corporation competitive advantage: The firms frequently compete for the same transformation deals, with Accenture winning on scale and IBM winning on technical depth. IBM doesn't operate hyperscale infrastructure and has no intention of doing so. If any hyperscaler decides to offer deeply integrated Kubernetes management that makes OpenShift less necessary, IBM's differentiation narrows. IBM's competitive advantage is invisible to anyone who evaluates technology companies by consumer brand recognition or developer mindshare. These systems are IBM's installed base, and the switching costs they represent are nearly infinite in practical terms. That installed base creates a gravity well that pulls in adjacent revenue. Each product sold deepens the relationship and raises the switching cost further. Red Hat's competitive advantage is different in kind but equally durable. The operational knowledge, security configurations, and integration work create switching costs that compound with each passing quarter. And because OpenShift runs on any cloud (AWS, Azure, GCP, on-premises), it positions IBM as the neutral orchestration layer in multi-cloud environments — a position no hyperscaler can credibly occupy because each one has an incentive to lock customers into its own stack. IBM Research is a third competitive advantage that defies easy financial quantification. The final advantage is institutional trust in regulated industries. That accumulated trust — knowing that IBM will still exist in 20 years, will comply with regulations, will provide support contracts, will not compromise data sovereignty — is a competitive asset that no startup and few hyperscalers can match. IBM's roadmap targets quantum advantage for specific enterprise use cases (drug discovery, financial risk modeling, materials science, supply chain optimization) by 2028-2030.

Novartis AG competitive advantage: This profile dissects the financial mechanics, historical pivots, and competitive moats of an organization that deliberately burned its safety net to achieve industry-leading growth in the most complex therapeutic areas known to modern medicine. The spin-off of Sandoz was not merely a financial transaction; it was a philosophical declaration that Novartis would no longer compete on manufacturing scale and cost efficiency, but solely on scientific differentiation and clinical efficacy. This logistical moat is complemented by the clinical data package surrounding Pluvicto, which demonstrated a 4.5-month improvement in overall survival in the VISION Phase III trial, a statistically significant and clinically meaningful endpoint that has cemented the drug's position as a standard of care in late-line prostate cancer. The immunology market is particularly vicious because patient switching costs are high, and physicians are reluctant to change therapies unless new data demonstrates superior long-term outcomes. This dynamic creates a constant tension between internal R&D productivity and external capital deployment, a balance that CEO Vas Narasimhan has managed by strictly prioritizing acquisitions that offer late-stage, de-risked assets in areas where Novartis already has commercial scale. Novartis entered this highly competitive space with Kesimpta, a subcutaneous formulation of a similar anti-CD20 antibody, which offers the significant advantage of at-home self-administration compared to the intravenous infusion required for Ocrevus. The barrier to entry is not just scientific; it is logistical. Building a global network of nuclear pharmacies and certified treatment centers takes a decade and hundreds of millions in capital expenditure, a timeline that gives Novartis a first-mover advantage that is virtually impossible to close quickly. These two pillars — radioligand oncology and rare complement diseases — represent a competitive advantage that is rooted in deep scientific expertise, massive capital barriers, and regulatory exclusivity, creating a defensive perimeter that pure-play biotech startups and diversified pharma giants alike will struggle to penetrate before 2030. The clinical data package surrounding Pluvicto further solidifies this competitive advantage. The company's investment in the manufacturing capacity for radioligands is another critical component of its competitive moat. The sheer cost and regulatory complexity of building and operating these facilities deter all but the most well-capitalized competitors from attempting to enter the radioligand space, giving Novartis a significant cost and scale advantage that will be difficult to replicate. This regulatory expertise, combined with its manufacturing scale and clinical data dominance, creates a comprehensive competitive advantage that positions Novartis as the undisputed leader in the rapidly evolving field of targeted radionuclide therapy. If these trials are successful, Novartis could potentially launch the first FAP-targeting radioligand therapy by 2028, establishing another first-mover advantage in a completely new therapeutic area and creating a multi-billion dollar revenue stream that would significantly diversify the company's oncology portfolio. Novartis has established a dedicated AI and data science hub in Cambridge, Massachusetts, which is focused on developing machine learning algorithms to analyze large-scale biological datasets, identify novel drug targets, and optimize the design of clinical trials.

Future prospects matter as much as current results. The growth strategies below explain how International Business Machines Corporation and Novartis AG each plan to expand from here.

International Business Machines Corporation growth strategy: The company spun off its managed infrastructure services as Kyndryl Holdings in November 2021 to focus on higher-margin software and consulting. It's not growing in unit terms, but it generates extraordinary cash flow. The problem is, the quantum race is still early enough that leadership positions could shift, but IBM's systematic roadmap (from 1,121 qubits today toward 100,000+ qubits by 2033) and enterprise-focused approach give it a credible claim to being the default choice for enterprise quantum adoption. IBM's financial narrative is a story of deliberate portfolio compression — trading top-line revenue for higher margins, better growth quality, and a more predictable earnings stream. Pre-tax income margins expanded as IBM shed the lower-margin Kyndryl business (managed infrastructure operated at roughly 15-18% margins) and invested in higher-margin software. For investors, the critical metrics are: Software revenue growth (needs to sustain high-single-digits to justify the valuation re-rating), consulting book-to-bill ratio (a leading indicator of future revenue), and Red Hat's growth rate (the canary in the coal mine for the entire hybrid cloud thesis). If they accelerate, IBM's stock — which has already more than doubled from its 2022 lows — has further to run. Ask a CIO at a Fortune 500 bank about IBM and you'll hear 'critical infrastructure partner' and 'Red Hat' and 'we're evaluating watsonx.' These are two different realities, and IBM has to win in both simultaneously. The engineers who would be most effective building enterprise AI tools often prefer to work on the sexier frontier models, even if the enterprise work is more commercially important. This means IBM's hybrid cloud strategy depends on Red Hat's software running on other companies' infrastructure — a position that creates genuine value for customers but also means IBM is building on top of its competitors' foundations. While no one is migrating their mainframe workloads tomorrow, the generational change in IT leadership means that new CIOs are less likely to have grown up with z/OS and more likely to default toward cloud-native architectures for new workloads. IBM needs to convince each generation of technology leaders that the mainframe is a modern platform worth investing in, not a legacy system to be replaced when the older engineers retire. Once an organization standardizes on OpenShift for container orchestration, its developers write code, build pipelines, and manage deployments using OpenShift-specific patterns. IBM's growth strategy under Arvind Krishna is built on three interconnected pillars: expand hybrid cloud adoption through Red Hat, become the enterprise AI platform of choice through watsonx, and use consulting as the delivery mechanism that pulls both through. IBM's growth thesis is that each new application modernized onto OpenShift increases the customer's Red Hat consumption and creates opportunities for adjacent IBM software (automation, security, data). The land-and-expand motion within existing accounts is more reliable than new customer acquisition and carries lower sales costs. Watsonx is the AI growth vector. The strategy is not to compete with OpenAI on model capability but to compete on enterprise deployment — helping companies fine-tune models on their proprietary data, deploy them inside their security perimeter, and govern their use across the organization. Early traction includes partnerships with SAP, Salesforce, and Adobe to embed watsonx capabilities into their enterprise applications. Here's why: if AI governance and compliance become mandatory (likely given EU AI Act and similar regulations), IBM's early investment in trustworthy AI positions it as a compliance-ready platform. Consulting growth depends on the structural demand for technology transformation. IBM Consulting's growth strategy is to increase the proportion of engagements that include IBM software, creating a consultative selling motion where the consulting team identifies opportunities and pulls through Software revenue. This 'Consulting-to-Software' flywheel is the core of IBM's cross-segment growth thesis. Acquisitions continue to play a role, focused on tuck-in purchases that add capabilities to the platform. Geographic expansion targets growth markets where digital transformation is earlier stage — India, Southeast Asia, the Middle East, and Africa. Watsonx and enterprise AI represent IBM's most significant growth opportunity since the mainframe era. If quantum delivers on its theoretical promise, IBM's decade-long head start in building quantum hardware, developing quantum algorithms, and building an enterprise quantum user base could create a new $10-50 billion annual market. If quantum remains laboratory-grade for another decade, the investment is manageable but the payoff is delayed. The most likely outcome for IBM over the next five years: steady mid-single-digit revenue growth driven by Software and Consulting, continued margin expansion, increasing free cash flow that supports dividend growth and tuck-in acquisitions, and gradual re-rating from 'legacy tech' to 'hybrid cloud and AI platform company.' Not exciting by startup standards.

Novartis AG growth strategy: The decision to abandon low-margin, high-volume generic manufacturing in favor of high-risk, high-reward specialty therapeutics was orchestrated by CEO Vas Narasimhan, who took the helm in 2018 and immediately recognized that the conglomerate structure was destroying shareholder value by masking the true growth rate of the innovative pipeline. The FY2025 financial results reveal a company in the midst of a high-wire act: replacing declining legacy blockbusters with next-generation modalities while maintaining double-digit earnings growth. This pivot has alienated income-focused investors who relied on the steady dividends of the generics business, but it has attracted a new class of growth-oriented institutional capital that values the binary upside of a successful Phase III oncology trial over the single-digit margins of commodity pill manufacturing. The execution of this strategy requires flawless commercial execution, a capability that was severely tested in FY2025 when Entresto, the company's premier cardiovascular franchise, faced generic competition in the United States. This logistical constraint creates a massive barrier to entry for competitors, as it requires the establishment of a decentralized network of nuclear pharmacies and certified treatment centers, a capital-intensive infrastructure that Novartis has spent the last seven years building through strategic acquisitions and organic investment. The ultimate goal of the business model is to achieve a sustainable compound annual growth rate (CAGR) of 5-6% at constant currency through 2030, a target that requires the successful launch of at least eight new molecular entities currently in the late-stage pipeline. The market has rewarded this strategy with a higher valuation multiple, recognizing that a pure-play innovator with a strong pipeline is worth more than a diversified healthcare conglomerate, and the FY2025 financial results provide the empirical evidence that this strategic gamble is currently paying off, even as the company navigates the treacherous waters of the Entresto patent cliff. To mitigate these patent cliff risks, the business model incorporates aggressive inorganic growth. This bolt-on acquisition strategy is designed to fill the revenue gaps left by patent expirations without relying solely on internal discovery. Novartis has invested hundreds of millions of dollars to build a network of specialized nuclear pharmacies and certified treatment centers capable of handling radioactive materials, creating a massive barrier to entry for competitors who would need to replicate this infrastructure from scratch. For Cosentyx, the company has continuously expanded the label to include new indications such as non-radiographic axial spondyloarthritis and enthesitis-related arthritis, while also launching higher-concentration, single-use autoinjectors to improve patient compliance and convenience. The company has consistently returned over 50% of its free cash flow to shareholders through a progressive dividend policy and an aggressive share buyback program, a strategy that has supported the stock price during the transition period between legacy patent cliffs and new product launches. The company's future depends on its ability to execute a 5-6% constant currency sales CAGR through 2030, a target that requires the successful launch of eight late-stage pipeline assets and the continued expansion of its dominant position in radioligand therapy. Novartis's competitive strategy in this space relies on continuous lifecycle management, launching new indications and delivery methods to extend patent life. The most significant competitive threat, however, comes from the rise of specialized biotechnology companies that focus exclusively on single therapeutic areas. To counter this, Novartis has adopted a 'buy and scale' strategy, using its massive balance sheet to acquire clinical-stage biotechs like MorphoSys and Chinook, effectively outsourcing the early-stage discovery risk to the private markets and then using its global commercial infrastructure to maximize the value of the assets. This convenience factor has driven rapid uptake of Kesimpta, allowing Novartis to capture a significant portion of the market despite entering several years after Ocrevus. Novartis has responded by aggressively expanding its oncology pipeline through both internal discovery and external acquisitions, focusing on novel targets and mechanisms of action that have the potential to overcome resistance to existing therapies. The company's acquisition of MorphoSys, for example, was driven by the desire to acquire pelabresib, a BET inhibitor that has shown promise in the treatment of myelofibrosis, a rare blood cancer with limited treatment options. This strategy of identifying unmet medical needs in rare and complex diseases and developing targeted therapies to address them is a core component of Novartis's competitive strategy, allowing the company to avoid the hyper-competitive, price-sensitive markets for common diseases like diabetes and hypertension, and instead focus on areas where it can command premium pricing and achieve high margins. Selling, general, and administrative expenses were tightly controlled, growing at a slower rate than revenue, which contributed to the margin expansion. This capital return strategy is designed to support the stock price during the transition period between legacy patent cliffs and new product launches, signaling management's confidence in the long-term cash generation capabilities of the pure-play innovative model. This substantial R&D investment is critical for maintaining the company's competitive position and driving future growth, and it is allocated across a diverse portfolio of early-stage discovery programs, Phase I and II clinical trials, and large-scale Phase III registrational studies. Selling, general, and administrative (SG&A) expenses were $14.1 billion, or 25.9% of net sales, reflecting the significant commercial investment required to launch and support the company's growing portfolio of innovative medicines. Additionally, the company faces significant headwinds in the Chinese market, which has historically been a key driver of volume growth for its portfolio. The Chinese government's Volume-Based Procurement (VBP) program has forced steep price cuts on older, off-patent drugs, and the National Reimbursement Drug List (NRDL) negotiations have increasingly targeted newer, innovative therapies, compressing margins and limiting the revenue potential of new launches in the region. Novartis has responded by restructuring its commercial organization in China, shifting its focus toward a smaller portfolio of high-value innovative medicines and divesting its low-margin off-patent portfolio to local partners, but the long-term impact of these regulatory pricing pressures on the company's growth trajectory in Asia remains a significant area of uncertainty for investors. Novartis is currently conducting the PSMAddition trial to evaluate Pluvicto in an earlier line of therapy, which, if successful, would expand the addressable patient population by several fold and further entrench the drug's dominance in the prostate cancer treatment algorithm. Novartis AG's growth strategy is built on three specific, named initiatives with clear financial targets: the acceleration of radioligand therapy launches, the aggressive expansion of the rare disease portfolio through bolt-on acquisitions, and the lifecycle management of key immunology franchises. The company has committed to launching at least eight new molecular entities or major label expansions between 2025 and 2030, a pipeline that includes potential blockbusters in oncology, immunology, and cardiovascular disease. The radioligand initiative is the cornerstone of this strategy, with the company investing heavily in manufacturing capacity and clinical trials to expand Pluvicto into earlier lines of prostate cancer and launch new FAP-targeting therapies for solid tumors. The rare disease growth strategy focuses on using the Chinook Therapeutics acquisition to establish Novartis as the leader in complement-mediated diseases. The immunology lifecycle management strategy aims to extend the commercial life of Cosentyx and Kesimpta by launching new indications, combination therapies, and subcutaneous delivery methods. By continuously expanding the clinical utility of these assets, Novartis can defend against biosimilar competition and maintain premium pricing in key markets. To fund these initiatives, the company maintains a disciplined capital allocation framework that prioritizes R&D investment and strategic acquisitions over large-scale, transformational mergers. The execution of this growth strategy requires a highly skilled and motivated workforce, and Novartis has invested heavily in talent acquisition and development to ensure that it has the necessary scientific and commercial expertise to succeed. Novartis has also implemented a comprehensive training and development program for its employees, focusing on building the skills and capabilities required to succeed in the rapidly evolving pharmaceutical industry. The company's culture of innovation and collaboration is a key enabler of its growth strategy, fostering an environment where employees are encouraged to think creatively, take calculated risks, and work together to solve complex scientific and commercial challenges. The growth strategy also includes a strong focus on sustainability and corporate social responsibility, recognizing that the long-term success of the company is inextricably linked to the health and well-being of the communities in which it operates. Novartis has committed to achieving net zero greenhouse gas emissions across its value chain by 2040, and has implemented a comprehensive environmental, social, and governance (ESG) program that focuses on reducing its environmental footprint, promoting diversity and inclusion, and ensuring access to healthcare for underserved populations. The company's ESG initiatives are integrated into its overall business strategy, and its performance against these goals is regularly monitored and reported to stakeholders. The successful execution of Novartis's growth strategy will require the company to navigate a complex and dynamic external environment, characterized by rapid technological change, intense competition, and evolving regulatory and pricing pressures. However, the company's strong scientific heritage, strong pipeline, and disciplined capital allocation strategy provide a solid foundation for future growth, and its commitment to innovation and patient-centricity positions it well to deliver on its strategic objectives and create significant value for all stakeholders. The company projects a 5-6% constant currency sales CAGR from 2025 to 2030, a growth rate that relies heavily on the successful commercial launch of at least eight late-stage pipeline assets currently in Phase III trials. In the rare disease space, the integration of the Chinook Therapeutics assets is expected to drive significant revenue growth in IgA nephropathy and atypical hemolytic uremic syndrome, therapeutic areas where Novartis now holds a near-monopoly position. Novartis has partnered with leading AI companies to identify novel biological targets and predict patient responses to therapy, a strategy that could significantly reduce the time and cost required to bring new drugs to market. In addition to radioligands, Novartis is heavily invested in the development of gene therapies and RNA-based therapeutics, modalities that have the potential to provide curative treatments for rare genetic diseases. The company's pipeline includes several gene therapy programs for inherited retinal diseases, spinal muscular atrophy, and cardiovascular diseases, as well as a strong portfolio of siRNA and mRNA therapeutics developed through its internal research and external partnerships. Novartis has invested heavily in its gene therapy manufacturing facilities in New Jersey and Germany, and has established a dedicated commercial team to support the launch of these complex therapies. The company is also exploring the use of digital biomarkers and wearable devices to collect real-time patient data during clinical trials, which could provide more sensitive and objective measures of drug efficacy and accelerate the regulatory approval process. The successful implementation of these digital health initiatives has the potential to significantly improve the productivity of the company's R&D organization and reduce the attrition rate of clinical candidates, ultimately leading to the faster and more efficient development of new medicines. The company faces intense competition in all of its key therapeutic areas, and the failure of any of its late-stage pipeline assets could have a material adverse impact on its financial performance and growth trajectory. Despite these challenges, Novartis's strong portfolio of innovative medicines, strong pipeline, and disciplined capital allocation strategy position it well to deliver sustained long-term growth and create significant value for its shareholders. However, the conglomerate structure eventually became a burden, masking the true growth rate of the innovative pipeline and depressing the company's valuation multiples.

A closer look at the financial trajectory of International Business Machines Corporation and Novartis AG rounds out the comparison.

International Business Machines Corporation: $67.5B in FY2025 revenue, up from $61.9 billion in FY2023 and $60.5 billion in FY2022. The growth is consistent but not dramatic — a company executing a multi-year portfolio transition rather than riding a cyclical wave. The Kyndryl separation in 2021 removed approximately $19 billion in lower-margin managed infrastructure revenue, which is why the comparison to pre-2021 revenue figures is not straightforward. The software segment operates at gross margins around 80%. Consulting gross margins sit at 27-29% — lower, but strategically essential because consulting engagements drive software adoption. A client engagement that starts with a consulting project typically ends with multi-year software licensing agreements. The revenue mix between these two segments determines the blended margin profile. Market capitalization of $230 billion against $62.8 billion in revenue implies a 3.7x price-to-sales multiple — above the historical range for IBM, reflecting the market's willingness to price the Red Hat hybrid cloud thesis more generously than it priced the traditional services model. The Apptio acquisition in 2023 for an undisclosed price added IT financial management software that complements the Red Hat infrastructure layer. The quantum computing investment is the longest-horizon bet in the portfolio. IBM has been the most consistent commercial investor in quantum computing of any major technology company. The timeline to commercially relevant quantum advantage remains uncertain, but the intellectual property position being built is real and could represent significant value in a post-2030 computing environment.

Novartis AG: Free cash flow of $17.6 billion in FY2025 on $54.5 billion in net sales represents a free cash flow margin of approximately 32% — a number that reflects both the inherent economics of premium pharmaceutical manufacturing and the elimination of lower-margin generics revenue that had diluted the consolidated margin profile. Net income of $13.97 billion and operating income of $17.64 billion confirm that the Sandoz spin-off's financial impact has been exactly what Narasimhan projected. Revenue grew from $47.8 billion in FY2023 to $50.3 billion in FY2024 to $54.5 billion in FY2025, a trajectory that reflects the underlying growth rates of the key franchises: Entresto in heart failure, Cosentyx in immunology, Kisqali in breast cancer, and Pluvicto in prostate cancer. Each drug has a different patent timeline and pricing environment. The US accounts for approximately 45% of total global sales, where pricing power is highest but increasingly constrained by IRA negotiation authority. The $10.8 billion annual R&D expenditure — redirected from the Sandoz operation after the spin-off — finances a pipeline with over 20 programs in Phase III trials across oncology, immunology, cardiovascular, and neuroscience. The radioligand therapy infrastructure, which requires specialized manufacturing facilities and handling protocols for radioactive compounds, represents a capital investment that creates a genuine production barrier for competitors attempting to develop similar drugs. The market capitalization of $274.1 billion at fiscal year-end represents approximately 5x FY2025 net sales — a premium that reflects investor confidence in both the current commercial execution and the pipeline's depth. The MorphoSys acquisition in 2024, which added pelabresib, a potential treatment for myelofibrosis, extended the oncology pipeline in a direction where existing Novartis commercial infrastructure could support the launch without proportional incremental cost.